On November 12, 2026 Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company integrating diagnostics, therapeutics, and artificial intelligence, reported it will host a conference call on Monday, November 16, 2026, at 8:30 a.m. Eastern Time to review REYOBIQ ReSPECT-LM clinical data scheduled for presentation at SNO on November 13 and provide a CNSide commercial update. The Company will also report its third quarter 2026 financial results that day.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Webcast and Conference Call
Date/Time: Monday, November 16, 2026, at 8:30 AM ET
Webcast: View Source
Dial-in: U.S.: 833-862-0853
International: 412-365-5147
Please dial in 15 minutes prior to the start time.

Following the live call, a replay will be available on the Company’s website under the ‘For Investors’ section. The webcast will be available on the Company’s website for 90 days.

(Press release, Cerenome, NOV 12, 2026, View Source [SID1234674697])